Summit, Akeso look to shed PD-1/VEGF drug doubts with latest study results

Data ReadoutpositiveivonescimabPositive

AI Analysis

Summary

Summit and Akeso released new study results for ivonescimab, a PD-1/VEGF combination drug, showing positive data that impressed investors compared to a rival Merck medication.

Outcome Details

New findings impressed Wall Street

Importance:6/10

Sentiment:

0.65

clinical datacompetitive comparisonimmunotherapycombination therapy

Related Companies

$MRK

Read the original article

Published by BioPharma Dive on September 14, 2026 8:41 PM

Read Original